Cellestia Biotech hat dies direkt geteilt
Excited to present Cellestia Biotech at Bio 2024. Reach out to learn more about our science and clinical development program at Swiss pavilion (booth 2111).
Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)
Externer Link zu Cellestia Biotech
Hochbergerstrasse
Basel, Basel-Town 4057, CH
Superlab Suisse– SERINE, Route de la Corniche 6
Epalinges, CH
Cellestia Biotech hat dies direkt geteilt
Excited to present Cellestia Biotech at Bio 2024. Reach out to learn more about our science and clinical development program at Swiss pavilion (booth 2111).
Cellestia Biotech hat dies direkt geteilt
This week, four Swiss #biotech startups joined us in Boston for a three-day program on their way to the BIO International Convention in San Diego next week. Meet the startups and find out more about their experience in Boston as part of the Innosuisse Internationalization Camps! 🚀 The startups are: Nagi Bioscience, whose SydLab System is a benchtop laboratory device allowing standardized drug and chemical testing on microorganisms within disposable microfluidic cartridges. mimiX Biotherapeutics which has developed FastSkin, a dermal substitute developed by mimiX using their Sound Induced Morphogenesis technology, offers a novel solution to help patients struggling to heal from complex wounds. Cellestia Biotech is a fully integrated R&D company specialized in innovative therapeutics with new modes of action to treat autoimmune diseases and multidrug resistant cancers. Amphilix AG is developing small molecular chimeras utilizing a unique linker platform that enables fine-tuning of molecular properties, raising the bar for standard-of-care treatment and addressing unmet medical needs. Here’s what they’ve been up to this week: ⚖️ In a session on incorporation with Laura Stoffel (Gunderson Dettmer) they discussed types of legal structures in the US and their implications. 👨💻 With Alexander Harrall (TriNet) they learned how to hire in the US and discover cultural differences in the recruitment process to attract the best talent. 📃 James Ravitz (McDermott Will & Emery) shared insights on the FDA’s regulatory approval process and got them ready for expansion. 🧪 With Alberto Nobili, the startups got the chance to tour Bayer Co.Lab, an incubator for early-stage healthcare startups. 👥 In a feedback session with investors Doug Zingale and Edward Melia the startups got invaluable advice on their pitches and practiced how to adjust them to the local audience. 🗃️ In a session on taxation with Gerhard Friedrich Schneiders (Rödl & Partner USA) they discussed differences between Switzerland and the US, and the tax implications of different legal entities. 📣 Finally, with Mehdi Aghdaee, MD, PhD (#QuantLifeSciences), they worked on their storytelling skills, practicing how to create a storyline and capture an audience - which will come in handy next week! We welcomed the startups to the US with our Biotech Garden Party, where they were able to meet and network with members of Boston’s biotech community, including representatives from Novartis, Sanofi, Pfizer, and many others who will be attending #BIO2024. Thanks to all who attended the event, and especially to Innosuisse, Greater Zurich Area, Greater Geneva Bern area (GGBa), and Switzerland Global Enterprise for their partnership. Thank you as well to all the experts who shared their time and knowledge with the startups throughout the week! 🙏🏼 Next stop, San Diego! 🌴 #SwissBiotech #SwissStartups
Cellestia Biotech hat dies direkt geteilt
Thrilled to join the Treg-Directed Therapies Summit alongside industry peers as an Expert Speaker. We will unveil cutting-edge research from Cellestia Biotech on modulating Treg cells to tackle autoimmune diseases. Stay tuned..
Cellestia Biotech hat dies direkt geteilt
I will be attending Bio-Europe in Barcelona. Get in touch to learn more about Cellestia's pipeline and innovative approach to address autoimmune and inflammatory diseases. Informa Connect
Follow Raj Lehal, PhD, Cellestia Biotech CEO, presenting at the 6th Treg Summit in Boston on May 21-23, 2024! #treg #tregcells #autoimmunity
🚨🚨Calling all Treg Therapy enthusiasts🚨🚨 I am pleased to announce that the Treg Directed Therapies Summit is back for its sixth edition and we are thrilled to unveil the official agenda. Be among the first to view the agenda here: https://ter.li/ce5oi5 Across 30+ presentations, explore cutting-edge insights with brand new data and propel your knowledge of Treg Therapies to progress clinical development and meet therapeutic milestones. Here’s a sneak peak at our expert speaker faculty: Marc Martinez-Llordella - Quell Therapeutics David Klatzmann - Sorbonne University Thomas Wickham - GentiBio Sean O'Bryan - Sonoma Biotherapeutics Melanie Kleinschek - TrexBio Ellen Cahir-McFarland - Abata Therapeutics Kyle Bednar - AstraZeneca Raj Lehal, PhD - Cellestia Bio Arpita Maiti - AbbVie Kristine Swiderek - Mozart Therapeutics Ethan Shevach - NIAID / NIH Leonard Dragone - Abata Therapeutics Saifur Rahman, PhD, MBA - Sanofi Zinaida Good, Ph.D. - Stanford University Amy Rosenberg - EpiVax Todd McDevitt, PhD - Genentech Kei Kishimoto - Selecta Biosciences Laura Solforosi, PhD - Genmab Denise Faustman - Harvard Medical School ... and more!! #treg #celltherapy #tregtherapy #CARTreg #regulatorytcell #IL2 #cartcelltherapy #tregcells #autoimmunity (Hanson Wade Group)
Cellestia Biotech is proud to announce its selection for a CHF 2 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Start-up Innovation project to advance to clinical Proof of Concept a first-in-class therapy for prevention of Graft vs Host Disease (GvHD). To read the Press Release: https://lnkd.in/eicS9jwW
Our CEO Raj Lehal, PhD will be attending #jpmorgan week 2024 in San Francisco from January 8-11. Set up a meeting to learn more about Cellestia Biotech and our exciting program!
The Cellestia Biotech team would like to wish you and your loved ones a wonderful holiday season!
Letzte Runde
Unterstützung ohne FremdkapitalInvestor:innen
Swissnex San Francisco